Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

Revolution Medicines' zoldonrasib shows 61% response rate in lung cancer patients with KRAS G12D mutations in Phase 1 trial, ...